IntelliPharmaCeutics Intl (IPCI) Upgraded by Zacks Investment Research to “Hold”

Share on StockTwits

IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. “

IPCI has been the topic of several other reports. HC Wainwright set a $3.00 price objective on IntelliPharmaCeutics Intl and gave the company a “buy” rating in a research note on Tuesday, May 29th. Maxim Group reiterated a “hold” rating and issued a $8.00 price objective on shares of IntelliPharmaCeutics Intl in a research note on Friday, June 15th. Finally, ValuEngine upgraded IntelliPharmaCeutics Intl from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $3.65.

NASDAQ:IPCI opened at $0.27 on Tuesday. IntelliPharmaCeutics Intl has a 52 week low of $0.23 and a 52 week high of $1.25. The firm has a market cap of $11.76 million, a price-to-earnings ratio of -0.91 and a beta of 1.14.

IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) last released its quarterly earnings results on Monday, July 16th. The company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $0.58 million for the quarter, compared to analyst estimates of $0.90 million. sell-side analysts predict that IntelliPharmaCeutics Intl will post -0.2 EPS for the current fiscal year.

An institutional investor recently bought a new position in IntelliPharmaCeutics Intl stock. Anson Funds Management LP acquired a new stake in IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,128,720 shares of the company’s stock, valued at approximately $1,210,000. IntelliPharmaCeutics Intl makes up about 0.9% of Anson Funds Management LP’s portfolio, making the stock its 17th largest holding. Anson Funds Management LP owned approximately 4.89% of IntelliPharmaCeutics Intl at the end of the most recent reporting period. Institutional investors and hedge funds own 20.52% of the company’s stock.

IntelliPharmaCeutics Intl Company Profile

IntelliPharmaCeutics International Inc, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain.

Further Reading: Diversification in Investing

Get a free copy of the Zacks research report on IntelliPharmaCeutics Intl (IPCI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply